Persistent SARS-CoV-2 infection

People with persistent SARS-CoV-2 infection can access a range of COVID-19 treatments from New Zealand’s portfolio.

Using the access criteria below, clinicians in Te Whatu Ora Hospitals can access the following treatments to treat persistent SARS-CoV-2:

Prescriptions must be endorsed by the prescriber confirming that the patient meets the following Access Criteria.

Initial Application – Treatment of persistent SARS-CoV-2 infection*

Access criteria - Any relevant practitioner 

Approvals are valid for patients where the prescribing clinician confirms the patient meets the following criteria and has endorsed the prescription accordingly. 

All of the following:

  1. Patient has laboratory confirmed diagnosis of persistent SARS-CoV-2 infection (≥20 days); and
  2. Patient is immunocompromised; and
  3. A multidisciplinary team (including an infectious disease physician) considers the treatment plan to be appropriate. 

Note: Indications marked with * are unapproved indications.